
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Daily antiviral therapy can prevent transmission of genital herpes simplex virus (HSV-2) from an infected individual to his or her partner, according to Stephen K. Tyring, M.D., Ph.D.






